Thrombus-targeted nanoparticles for thrombin-triggered thrombolysis and local inflammatory microenvironment regulation
Journal of Controlled Release, ISSN: 0168-3659, Vol: 339, Page: 195-207
2021
- 26Citations
- 18Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations26
- Citation Indexes26
- 26
- CrossRef6
- Captures18
- Readers18
- 18
Article Description
Thrombus related diseases seriously threaten human's health and life. The drawbacks of thrombolytic drugs, such as poor targeting ability and unexpected bleeding complications limit their clinical application. Thus, targeted delivery and controlled release of drugs at local thrombus sites to achieve efficient thrombolysis is an urgent event to be resolved. Herein, we developed an intelligent system MnO 2 /uPA@pep-Fuco for precise thrombolysis and thrombus inflammatory microenvironment remodeling. MnO 2 /uPA@pep-Fuco exhibited an excellent thrombus targeting ability via the high affinity of fucoidan (Fuco) for P-selectin overexpressed by activated platelets. And then pep-Fuco modified onto the surface of mesopore could be removed to release urokinase (uPA) locally under the high level of thrombin microenvironment in thrombus site. Meanwhile, due to the catalase-like activity of MnO 2 nanoplatform, MnO 2 /uPA@pep-Fuco could regulate the inflammatory thrombus microenvironment by eliminating hydrogen peroxide (H 2 O 2 ), so as to achieve a collaborative thrombolysis therapy. In ferric chloride (FeCl 3 )-induced carotid thrombus models, MnO 2 /uPA@pep-Fuco specifically targeted to the obstructive artery (3.43 times that of the normal artery) and significantly decreased the percentage of thrombus closure (5.99 ± 5.07%), demonstrating the superior thrombolysis ability. In addition, the significantly reduced tail bleeding time suggested MnO 2 /uPA@pep-Fuco might possess a low risk of bleeding complications.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0168365921003412; http://dx.doi.org/10.1016/j.jconrel.2021.06.043; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85116141142&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/34214595; https://linkinghub.elsevier.com/retrieve/pii/S0168365921003412; https://dx.doi.org/10.1016/j.jconrel.2021.06.043
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know